The Effect of Bevacizumab and Propranolol on Nasal Polyposis

Table 1

Expression of VEGF-A, Ang-1, Ang-2 in each group. (−: negative expression, +: Low expression, ++: Moderate expression and +++: High expression).

	VEGF-A	Ang-1	Ang-2
Group 1: Healthy nasal mucosa (control group)	−	+	+++
Group 2: Nasal polyposis group without any treatment	+	++	+
Group 3: Nasal polyposis + propranolol	−	−	++
Group 4 (n : 7): Nasal polyposis + bevacizumab	−	−	++